Anthracyclines are a potent class of chemotherapy agents used to treat cancer in chilhood and adults. Today there are five different anthracyclines approved for use as chemotherapeutics. All have been linked to the development of Anthracycline-induced-cardiotoxicity (ACT). ACT occurs in 57% of treated adult patients and 16% of children and remains an important limitation of anthracycline-based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified.
We offer a specififc genetic test aiming to identify the most important variants associated to ACT.
Why to offer genetic test in cases subjected to Anthracycline treatment??
- To reduce the possibility to develop heart complications after cancer therapy
- To monitor more closely drug levels in treated individuals
- To adjust medical therapy
Our Oncocardiology panel
It is single nucleotide polymorphism (SNP) based panel, aiming to identify specific variants associated to ACT identified in the following genes:
ABCC1, ABCC2, ABCC5, ATP2B1, CAT, CBR3, CELF4, CETP, CYBA, GPR35, GSTP1, HAS3, HER2, HFE, LPL, NOS3, PLCE1, RAC2, RARG, SLC22A17, SLC22A7, SLC28A3, SULT2B1, UGT1A6
What to expect from the test: This test will provide an estimated risk to develop cardiac disease based on the current knowledge.
- Reducing anthracycline-induced cardioxicity through pharmacogenetics. Scott E et al. Pharmacogenomics. 2018 Oct; 19(15):1147-1150.
- Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect. Leong SL et al. int J Cardiol. 2019 Apr 1;280: 190-197.
- Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.
Chang VY et al. Curr Oncol Rep. 2018 Apr 30;20(7):52
Download here interesting open access manuscripts on genetics of Oncocardiology: